As with most cancers, survival for NHL (all subtypes combined) is improving. Some of the increase is likely to be attributable to changes in the diagnosis, classification and registration of NHL, so interpretation of these trends should be undertaken with caution.
One-year
Non-Hodgkin Lymphoma (C82-C85), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011
Five- and ten-year survival has increased by an even greater amount than one-year survival since the early 1970s. Five-year age-standardised net survival for NHL in men has increased from 30% during 1971-1972 to a predicted survival of 68% during 2010-2011 in England and Wales – an absolute survival difference of 39 percentage points.[1] In women, five-year survival has increased from 31% to 70% over the same time period (a difference of 39 percentage points).
Non-Hodgkin Lymphoma (C82-C85), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011
Five-year survival for 2010-2011 is predicted using an excess hazard statistical model
Ten-year age-standardised net survival for NHL in men has increased from 22% during 1971-1972 to a predicted survival of 62% during 2010-2011 in England and Wales – an absolute survival difference of 41 percentage points.[1] In women, ten-year survival has increased from 22% to 64% over the same time period (a difference of 42 percentage points). Overall, more than 6 in 10 people diagnosed with NHL today are predicted to survive their disease for at least ten years.
Non-Hodgkin Lymphoma (C82-C85), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011
Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model
About this data
Data is for: England and Wales, 1971-2011, ICD-10 C82-C85